Accelerating Discovery from Lab to Patient

Enormous progress has been made in understanding what causes cancer. But at a time of great promise, there is a dire shortage of the very people who can take this knowledge and turn it into new treatments for patients—clinical investigators. They are the ones who ultimately translate science into cures.

Accelerating Cancer Cures is a multi-million-dollar project that will train a new generation of exceptional clinical investigators capable of translating the latest scientific discoveries into new diagnostics and therapeutics for patients.The initiative also fosters communication and collaboration between academia and industry. Accelerating Cancer Cures is currently sponsored by some of the world’s leading companies: AbbVie, Amgen, Genentech, Merck, and Novartis.

The Collaborators

Accelerating Cancer Cures is supported by leading biopharmaceutical companies who are committed to finding new cures for cancer. Founded in 2011, the initiative has included numerous participants: AbbVie, Amgen, Celgene, Eli Lilly and Company, Genentech, Merck, Novartis, Pfizer, and Takeda Oncology. Competitors in the marketplace, these companies have a shared belief that funding young physician-scientists with a commitment to innovation in cancer research will have a profound impact on the next generation of cancer breakthroughs.

You can support our innovative researchers.

OUR LATEST DISCOVERIES

AN EMAIL CONFIRMATION HAS BEEN SENT TO YOU

Accelerating Discovery from Lab to Patient

The Collaborators

The Awardees

Advisory Committee

Accelerating Cancer Cures Research Symposium